AstraZeneca Reports Results of Evusheld in P-III (PROVENT) Trial for the Treatment of Symptomatic COVID-19
Shots:
- The P-III (PROVENT) pre-exposure prophylaxis trial evaluates Evusheld (300mg, IM) vs PBO in a ratio (2:1) in 5197 patients with symptomatic COVID-19 at 87 sites in the US, UK, Spain, France & Belgium
- The results showed a 77% reduction in risk of developing symptomatic COVID-19 in primary analysis & 83% in 6mos. follow-up analysis, no COVID-19-related deaths were observed while PK data showed that Evusheld concentrations remained elevated in serum for 6mos. & provide protection against COVID-19. The therapy was well tolerated with no safety issues
- In primary & follow-up analysis, symptomatic COVID-19 occurred in (0.2% vs 1.0%) & (0.3% vs 1.8%). The efficacy was consistent across patients subgroups
Ref: Businesswire | Image: AstraZeneca
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
